摘要
目的观察齐拉西酮与利培酮对精神分裂症患者治疗效果及其瘦素、脂联素水平的变化。方法将80例精神分裂症患者随机分为齐拉西酮组与利培酮组,共治疗8周,于基线、治疗后4、8周分别对患者行阳性和阴性症状量表(PANSS)评分、体质量指数、瘦素、脂联素行测定,试验结束后对结果进行统计分析。结果两组治疗后4、8周评分与基线评分比较显著下降,差异有统计学意义(P<0.05)。利培酮组治疗后体质量指数、瘦素水平增加明显,脂联素水平明显下降,与治疗前基线比较差异有统计学意义(P<0.05)。结论齐拉西酮与利培酮治疗精神分裂症疗效相当。齐拉西酮对精神分裂症患者的体质量、瘦素水平及脂联素水平无明显影响,利培酮则影响明显,长期服用需注意其不良反应。
Objective To observe the effects of ziprasidone and risperidone on schizophrenia patients and the change of serum leptin and adiponectin levels.Methods Totally 80 cases of schizophrenia patients were randomly divided into ziprasidone group and risperidone group,which were treated for 8 weeks.Measure the positive and negative symptoms scale（PANSS）score and body weight of that number,leptin and adiponectin at baseline,treatment 4weeks and 8weeks respectively for patients,at the end of the experiment,the results for statistical analysis.Results Two groups of 4,8 weeks after treatment scores compared with baseline scores dropped significantly,the difference was statistically significant（P0.05）.Risperidone group after treatment,leptin levels significantly increased body mass index,and adiponectin levels significantly decreased,compared with the baseline before treatment was statistically significant difference（P0.05）.Conclusion Ziprasidone and risperidone in treatment of schizophrenia have similar efficacy.Ziprasidone has no significant effect on body weight,leptin and adiponectin levels in treatment of schizophrenia patients.However,risperidone has a significant effect,long-term use should pay attention to the side effects.
出处
《国际检验医学杂志》
CAS
2016年第4期506-507,510,共3页
International Journal of Laboratory Medicine
基金
佛山市医学类科技攻关项目(2014AB001693)
